Reimbursed Care Access in Brazil

Clinical research pathway but no registered medical product or routine reimbursed care. Multiple independent Brazilian groups have sought and in some cases registered clinical trials testing psilocybin for safety and for indications such as treatment‑resistant depression; for example a safety/tolerability study was registered on the Brazilian clinical trials platform (REBEC RBR-37qx63d). #

Regulatory context: psilocybin remains a controlled/forbidden substance in routine practice under Brazil’s drug control framework (Lei nº 11.343/2006) and substances listed in Portaria SVS/MS nº 344/1998. Research with psilocybin therefore requires specific regulatory routes: institutional ethics approval (CEP/CONEP), import or production authorization and, where necessary, an Anvisa special authorization or route for investigational products. There have been high‑profile administrative and judicial disputes between research sponsors and Anvisa about issuance of authorizations for clinical research, and Anvisa has at times stated that no authorization for commercial clinical trials had been identified — illustrating that trial approvals are possible but can be contested and are tightly regulated. # #

Payer/reimbursement: there is currently no public (SUS) reimbursement pathway for psilocybin‑assisted therapies because no approved medicinal product exists. Any future private insurance liability would depend on product registration by Anvisa and inclusion in regulatory/coverage lists; until that point access is limited to regulated clinical trials or unauthorized/illegal use (which carries criminal penalties under the drug law). #

Controlled for nonmedical use; clinical research permitted under authorization but no registered therapeutic product for routine care. MDMA (metylenedioximetanfetamina) is a psychotropic substance controlled in Brazil under Portaria SVS/MS nº 344/1998 and falls within the scope of the Lei nº 11.343/2006 for criminal prosecution if used/trafficked outside authorized channels. # #

Research and practice: Brazilian investigators have conducted MDMA‑assisted therapy research (published pilot work and small clinical series) and some studies have been conducted under local ethics approvals with Anvisa permission for importation or handling of investigational MDMA; these projects show that formal clinical trials can occur but MDMA has not been registered as a routine therapeutic medicine in Brazil. Examples of local academic activity and pilot trials have been reported in national media and in trial summaries; regulatory acceptance is research‑by‑research and requires CEP/CONEP and Anvisa controls. #

Payer/reimbursement: no SUS or standard private‑insurance reimbursement exists for MDMA‑assisted therapy because there is no approved marketed MDMA medicinal product in Brazil. Access is limited to authorized clinical trials and to investigational programs; off‑label clinical use in routine care would be unlawful and subject to criminal sanction under the drug law unless/until an Anvisa marketing authorization and coverage decision are obtained. #

Esketamine (Spravato® / cloridrato de escetamina) is approved and registered by ANVISA with specific psychiatric indications and is intended for administration in controlled clinical settings. ANVISA published the registration for SPRAVATO® (cloridrato de escetamina) with indication for treatment‑resistant major depressive disorder in adults (used in combination with an oral antidepressant) and for rapid reduction of depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior; the registration information and publishing in the Official Journal are available on ANVISA’s website (publication in the DOU 03/11/2020). #

Regulatory and delivery details: because esketamine is an intranasal product with acute hemodynamic and dissociative effects it is subject to risk‑mitigation measures and must be administered under clinical supervision (clinic/hospital setting) consistent with its product label. Different manufacturers have sought additional esketamine registrations (including other active‑ingredient dossiers) and Anvisa activity on esketamine has continued after the first registration. #

Coverage and reimbursement: esketamine is a registered medicine (so private health plans may be required to provide it when medically indicated), but it is not a routinely listed procedure in SUS treatment protocols and wide public reimbursement is not automatic. Brazilian case law has established that private health insurers can be ordered to provide registered medicines when clinically justified (even if not in the ANS Rol), meaning patients have used judicial mechanisms to gain coverage from private plans for esketamine in individual cases. Pricing and per‑session clinic costs are high (reports in the Brazilian press and legal analyses cite per‑session figures in thousands of BRL), and routine public reimbursement through SUS would require formal inclusion in public protocols and budgets. # #

Ketamine (racemate) is an established anesthetic registered for perioperative/analgesic use and is commonly used off‑label in psychiatry (intravenous infusions, sub‑anesthetic dosing) across Brazil in private clinics and some hospital services for treatment‑resistant depression and other indications. Its medical use as an anesthetic is long standing; psychiatric/psychedelic applications are largely off‑label clinical practice or conducted through research protocols and local institutional governance. Off‑label IV ketamine infusion services are widely provided in private settings; documentation and practice standards vary regionally and are subject to medical‑ethical oversight by local health authorities and professional colleges. #

Reimbursement: public (SUS) coverage for ketamine as routine psychiatric therapy is not standardized; when ketamine is used for anesthesia in registered indications it is reimbursable within normal SUS/hospital billing, but off‑label psychiatric infusion programs are usually paid privately. Private health plans may be required to cover authorized, evidence‑based uses, but off‑label psychiatric infusion programs commonly rely on private payment or individual judicial claims. Clinical protocols, dosing and monitoring standards should follow institutional review and national medical guidelines where available. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research; however the use of ayahuasca (a plant brew that contains DMT) is expressly authorized for ritual/religious use under CONAD resolutions and related administrative practice. The active molecule DMT itself is listed under Brazil’s controlled‑substance lists (Portaria SVS/MS nº 344/1998 / Lei de Drogas), meaning manufacture, possession or distribution of pure DMT outside authorized channels is unlawful. # #

Religious exception: CONAD and its multidisciplinary working group produced resolutions and administrative norms recognizing and regulating ritual/religious use of ayahuasca by groups such as União do Vegetal and Santo Daime; those rules allow ritual use in organized religious settings but explicitly prohibit commercial sale or diversion beyond ritual contexts. The ayahuasca exemption is administrative (CONAD resolutions and follow‑on normative texts) rather than a decriminalization of pure DMT outside those ritualized, regulated settings. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Possession, manufacture or distribution of 5‑MeO‑DMT is subject to penal provisions in the Lei nº 11.343/2006 and the substances lists implemented via Portaria 344/1998. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Ibogaine is not part of routine medical care and its use/possession outside approved, authorized research or regulated compassionate programs would contravene Brazil’s drug control regime (Lei nº 11.343/2006 and Portaria lists). #

Ayahuasca (the traditional Banisteriopsis caapi + Psychotria/other admixture brew) is explicitly permitted for ritual and religious use in Brazil under CONAD resolutions and related administrative instruments; CONAD’s regulatory work and subsequent normative publications recognize ritual use and set procedures/limits (including prohibitions on commercial sale and measures for protecting minors and pregnant women in some contexts). ANVISA’s substance lists classify DMT as controlled, but the CONAD administrative framework functions as a specific exception for organized ritual use of the plant brew. This is an administrative/regulatory exemption (not a wholesale removal from drug control lists for the pure alkaloid). # #

Health and commercialization limits: judicial decisions and recent court cases emphasize that commercialization or sale of ayahuasca outside religious ritual contexts may trigger drug‑trafficking or other criminal charges; municipal/state oversight, certification or registration practices for religious groups are evolving and vary regionally. Entities using ayahuasca for non‑ritual commercial therapeutic services face substantial legal risk under existing law and jurisprudence. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. While certain botanical sources (cacti) may be legally sold as ornamental plants in some jurisdictions, extraction or use of mescaline as a psychoactive is controlled and subject to the Lei nº 11.343/2006 and Portaria 344/1998 provisions; commercialization or preparation for ingestion can attract criminal liability. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. The family of 2C-series synthetic phenethylamines (e.g., 2C-B) are captured by Brazil’s controlled‑substance lists and any non‑authorized possession, manufacture or distribution is prosecutable under the Lei nº 11.343/2006 and implementing Portaria rules. Clinical research would require formal Anvisa and ethics approvals. #